BBO-850 Receives Fast Track Designation for NSCLC Treatment
The FDA granted fast track designation to BBO-8520 (BridgeBio Oncology Therapeutics) for the treatment of patients with previously treated KRASG12C-mutated metastatic non-small cell lung cancer (NSCLC).1 Currently, the treatment is undergoing evaluation in …